FY25 Performance Recap - Record revenue of $1.138 billion, up 1.1% versus prior year[8] - Adjusted Diluted EPS up 7.3% versus prior year[8] - $52 million in FY25 share repurchases[8] Financial Highlights - Q4 Revenue of $296.5 million, up 7.0% vs prior year on an organic basis[33] - Q4 Adjusted EBITDA of $104.4 million compared to $90.4 million prior year[33] - Q4 Adjusted EPS of $1.32, up 28.7% compared to $1.02 prior year[33] - Full year Adjusted EBITDA of $374.5 million compared to $373.9 million prior year[32] - Gross Margin of 55.8% consistent with expectations[35] - A&M of 13.7% of Revenue[38] - G&A of 9.5% of Revenue[38] FY26 Outlook - Revenues of $1.140 to $1.155 billion[48] - Organic growth of approximately 1% to 2%, excluding projected FX headwind[48] - Diluted EPS of $4.70 to $4.82[48] - Free Cash Flow of $245 million or more[48]

Company Overview - Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare business, Opella, to CD&R, while retaining a 48.2% stake [1] - The transaction generated approximately €10 billion in net cash proceeds for Sanofi [1] Opella's Position and Strategy - Opella is now an independent global leader in consumer healthcare, positioned for long-term success with a strong brand portfolio and international reach [3][5] - The company employs over 11,000 people and operates in 100 countries, with 13 manufacturing sites and four development centers [5] - Opella is the third-largest player in the OTC and vitamins, minerals & supplements market, serving over half a billion consumers globally [5] Future Outlook - CD&R aims to support Opella in becoming a global consumer health champion, leveraging its expertise in the consumer health sector [4] - Opella is focused on unlocking its full potential and driving value creation through innovation and exceptional talent [5]

Core Viewpoint - Prestige Consumer Healthcare Inc. is set to release its fiscal 2025 fourth quarter and year-end earnings on May 8, 2025, before market opening, followed by a conference call at 8:30 a.m. ET to discuss the results [1]. Company Overview - Prestige Consumer Healthcare Inc. markets, sells, manufactures, and distributes a wide range of consumer healthcare products across the U.S., Canada, Australia, and other international markets [4]. - The company's diverse portfolio includes well-known brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, Debrox®, Gaviscon® in Canada, Hydralyte®, and the Fess® line of products in Australia [4].